Pegylated Interferon-α2b and Lamivudine in Hepatitis B e Antigen-Positive Chronic Hepatitis B
Authors: Martijn J. ter Borg, Harry L.A. Janssen
Journal: Annals of Internal Medicine (2005)

Letters6 September 2005Pegylated Interferon-α2b and Lamivudine in Hepatitis B e Antigen-Positive Chronic Hepatitis BMartijn J. ter Borg, MD and Harry L.A. Janssen, MD, PhDMartijn J. ter Borg, MDFrom Erasmus Medical Center Rotterdam, 3015 GD Rotterdam, the Netherlands.Search for more papers by this author and Harry L.A. Janssen, MD, PhDFrom Erasmus Medical Center Rotterdam, 3015 GD Rotterdam, the Netherlands.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-143-5-200509060-00018 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:In Chan and colleagues' study of pegylated interferon in patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (1), the sustained virologic response (HBeAg seroconversion and hepatitis B virus DNA level less than 500 000 copies/mL) was 36% after 32 weeks of therapy with pegylated interferon-α2b plus 52 weeks of lamivudine. This percentage is comparable with the HBeAg seroconversion rates in 2 global studies investigating combination therapy with pegylated interferon and lamivudine for 1 year (2, 3). In one of these studies, coordinated by our group (2), patients were treated for 52 weeks with pegylated interferon-α2b and ...References1. Chan HL, Leung NW, Hui AY, Wong VW, Liew CT, Chim AM, et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med. 2005;142:240-50. [PMID: 15710957] LinkGoogle Scholar2. Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet. 2005;365:123-9. [PMID: 15639293] CrossrefMedlineGoogle Scholar3. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005;352:2682-95. [PMID: 15987917] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Martijn J. ter Borg, MD; Harry L.A. Janssen, MD, PhDAffiliations: From Erasmus Medical Center Rotterdam, 3015 GD Rotterdam, the Netherlands.Disclosures: None disclosed. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoA Randomized, Controlled Trial of Combination Therapy for Chronic Hepatitis B: Comparing Pegylated Interferon-α2b and Lamivudine with Lamivudine Alone Henry Lik-Yuen Chan , Nancy Wai-Yee Leung , Alex Yui Hui , Vincent Wai-Sun Wong , Choong-Tsek Liew , Angel Mei-Ling Chim , Francis Ka-Leung Chan , Lawrence Cheung-Tsui Hung , Yuk-Tong Lee , John Siu-Lun Tam , Christopher Wai-Kei Lam , and Joseph Jao-Yiu Sung Pegylated Interferon-α2b and Lamivudine in Hepatitis B e Antigen-Positive Chronic Hepatitis B Henry L.Y. Chan and Joseph J.Y. Sung Metrics Cited byDiagnostik und Therapie der Hepatitis 6 September 2005Volume 143, Issue 5Page: 391KeywordsAntigensChronic hepatitis BConflicts of interestDNAHepatitis BHepatitis B virusInterferonsPatients ePublished: 6 September 2005 Issue Published: 6 September 2005 Copyright & PermissionsCopyright © 2005 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...